Skip to main content

Table 2 Patients' characteristics according to cancer type

From: Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America

  Non-AIDS-defining cancers (n = 219) AIDS-defining cancers (n = 564) Combined (n = 783) P
Sex (n = 783), % (n)     <  0.001
 Female 28% (61) 14% (79) 18% (140)  
 Male 72% (158) 86% (485) 82% (643)  
Age at cancer diagnosis (n = 783), median (IQR) 45 (38–54) 37 (31–44) 39 (32–47) <  0.001
Year of cancer diagnosis (n = 783), median (IQR) 2009 (2006–2012) 2008 (2004–2011) 2008 (2005–2011) <  0.001
Years from HIV diagnosis to cancer diagnosis (n = 772), median (IQR) 5.26 (2.09–11.00) 0.82 (0.11–5.05) 1.67 (0.18–6.74) <  0.001
Years from cART initiation to cancer diagnosis (n = 749), median (IQR) 3.08 (0.50–8.48) 0.02 (−0.08–0.86) 0.19 (−0.06–2.87) <  0.001
Cancer diagnosis relative to cART initiation (n = 783), % (n)     <  0.001
 Cancer diagnosis after cART initiation 79% (172) 50% (283) 58% (455)  
 Cancer diagnosis before/at cART initiation/Did not start cART 21% (47) 50% (281) 42% (328)  
CD4 count (cells/μL) at cancer diagnosis (n = 537), median (IQR) 376 (229–573) 89 (29–230) 148 (44–364) <  0.001
HIV-1 RNA at cancer diagnosis (log10) (n = 422), median (IQR) 2.6 (2.6–3.7) 4.6 (2.6–5.2) 3.9 (2.6–5.0) <  0.001
HIV-1 RNA status (cut point = 400 copies/mL), % (n)     <  0.001
 Undetectable 70% (99) 31% (87) 44% (186)  
 Detectable 30% (42) 69% (194) 56% (236)  
Status (n = 783), % (n)     0.20
 Alive 67% (147) 72% (405) 70% (552)  
 Dead 33% (72) 28% (159) 30% (231)  
Follow-up (yrs) (n = 783), median (IQR) 2.17 (0.66–5.13) 2.62 (0.69–6.34) 2.51 (0.69–6.13) 0.18
  1. Numbers after percentages are frequencies. IQR: Interquartile range. Tests used: Pearson test for categorical variables; Wilcoxon Rank Sum test for continuous variables